PO.CL01.13 · 临床研究
利用 CosMx 空间分子成像仪对乳腺癌组织进行原位空间多组学刻画
In situ spatial multiomic profiling of breast cancer tissue utilizing the CosMx Spatial Molecular Imager
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
乳腺癌是加拿大女性癌症相关死亡的主要原因。治疗方面的进展凸显了肿瘤异质性以及不同分子亚型间肿瘤微环境多样细胞组成的重要性。单细胞成像技术的演进如今使研究人员在评估这些复杂细胞相互作用时能够纳入空间背景,从而在蛋白质组和转录组层面实现细胞和亚细胞分辨率。在本研究中,使用了一张来自跨分子亚型的 25 个乳腺癌组织块的 100 芯组织微阵列(TMA)。将单张 5 微米切片进行连续两轮染色,先使用 64 重免疫肿瘤学检测进行 CosMx SMI 蛋白质组刻画,随后使用 6K RNA 检测进行转录组刻画。总共按照 CosMx 多组学检测方案(MAN-10201-04)刻画了 102 个视野(FOV)。在蛋白质检测的质量控制之后,我们刻画了 175,139 个细胞,鉴定出每个细胞平均六十七种独特蛋白质。随后进行 6K RNA 检测染色,刻画了 120,797 个细胞,使用叠加的 FOV 图进行下游数据拼接,共鉴定出 6,176 个基因,每个细胞平均 365 个独特基因,每个细胞平均 556 个转录本。为检查细胞分型的一致性,我们将 HER2 确定为临床报告数据、蛋白面板纳入以及 RNA 面板纳入(ERBB2)之间一致的靶标。我们发现通过 CosMx SMI 测得的所有核心 HER2 表达与临床注释相符,且 HER2 蛋白表达与 ERBB2 基因表达在整个流动池中呈强相关(r=0.79,p=5.71e-23)。相反,Ki67 呈现弱相关(r=0.13,p=0.201),凸显了评估两种指标以辨别生物学过程完整图景的重要性。CELESTA 细胞分型在蛋白质组刻画中鉴定出乳腺组织中预期存在的各种结构细胞(脂肪、内皮、上皮和血管平滑肌细胞),以及各种免疫群体,包括 B 细胞、CD4+、CD8+ T 细胞、树突状细胞、自然杀伤细胞、中性粒细胞、巨噬细胞和成纤维细胞。这些发现在转录组数据中得到证实,InSituType 监督聚类(BreastCancer_Wu.RData)揭示了癌相关成纤维细胞(CAF)、肿瘤相关巨噬细胞(TAM)、肿瘤浸润淋巴细胞(TIL)、初始和记忆 B 细胞,以及基底型、HER2+、Luminal A 和 Luminal B 上皮细胞群体。在正在进行的工作中,我们继续整合蛋白质组和转录组数据,以进一步研究在 TMA 中发现的未知细胞群体,并对乳腺癌分子亚型间肿瘤上皮相互作用的根本差异进行分类。
查看英文原文 English abstract
Breast cancer is a leading cause of cancer-related death among Canadian women. Advances in treatment have underscored the importance of tumor heterogeneity, and the diverse cellular composition of the tumor microenvironment across molecular subtypes. The evolution of single cell imaging technologies now allows researchers to incorporate spatial context when evaluating these complex cellular interactions, allowing cellular and sub-cellular resolution across the proteome and transcriptome. In this study, a 100-core tissue microarray (TMA) from 25 breast cancer tissue blocks spanning molecular subtypes was utilized. A single 5-micron section was subjected to two consecutive rounds of staining for CosMx SMI proteomic profiling using the 64-plex Immuno-Oncology assay followed by transcriptomic profiling using the 6K RNA assay. In total, 102 fields of view (FOVs) were profiled following the CosMx Multiomic Assay protocol (MAN-10201-04). After quality control of the protein assay, we profiled 175,139 cells identifying a mean of sixty-seven unique proteins per cell. With subsequent staining for the 6K RNA assay, 120,797 cells were profiled, using the overlaid FOV map for downstream data stitching, identifying a total of 6,176 genes, a mean of 365 unique genes per cell, and a mean of 556 transcripts per cell. To check concordance of cell typing, we identified HER2 as a consistent target between the clinically reported data, inclusion in the protein panel and inclusion (ERBB2) in the RNA panel. We found all core HER2 expression measured via the CosMx SMI matched the clinical annotations, and a strong correlation between HER2 protein expression and ERBB2 gene expression across the entire flow cell (r=0.79, p=5.71e-23). Conversely, Ki67 displayed a weak correlation (r=0.13, p=0.201), highlighting the importance of evaluating both metrics to discern a full picture of biological processes. CELESTA cell typing identified various structural cells expected to be found in breast tissue within the proteomic profiling (adipose, endothelial, epithelial, and vascular smooth muscle cells), along with various immune populations including B cells, CD4+, CD8+ T-cells, dendritic cells, natural killer cells, neutrophils, macrophages, and fibroblasts. These findings were corroborated in the transcriptomic data, with InSituType supervised clustering (BreastCancer_Wu.RData) revealing populations of cancer associated fibroblasts (CAFs), tumor associated macrophages (TAMs), tumor infiltrating lymphocytes (TILs), both naïve and memory B cells, along with basal, HER2+, Luminal A and Luminal B epithelial cell populations. In ongoing work, we continue to integrate proteomic and transcriptomic data to further investigate unknown cell populations found across the TMA and categorize fundamental differences in tumor epithelium interactions across molecular subtypes of breast cancer.
利益披露 Disclosure
M. Hopkins, None..
O. De Sa, None.